HOTAIRM1 and hepatocellular carcinoma: The current research demonstrated that HOTAIRM1 is an independent drug resistance factor, significantly associated with the efficacy of lenvatinib in HCC and helpful for guiding HCC patient treatment decision-making as well as follow-up visits.